Molecular DNA test to confirm a diagnosis of biotinidase (BTD) deficiency when biotinidase enzymatic activity is low. To diagnose or rule out BTD deficiency, refer to Biotinidase, Serum (with Paired Normal Control) (0093362).
Polymerase Chain Reaction/Sequencing
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Background information for Biotinidase Deficiency (BTD) Sequencing:
Characteristics: Ataxia, hypotonia, developmental delay, respiratory problems, seizures, vision problems, hearing loss, alopecia, rash, candidiasis, metabolic ketolactic acidosis, organic aciduria and mild hyperammonemia.
Incidence: 1 in 60,000.
Inheritance: Autosomal recessive.
Cause: Deleterious BTD gene mutations.
Clinical Sensitivity: 99 percent.
Methodology: Bidirectional sequencing of the entire BTD coding region and intron-exon boundaries.
Analytical Sensitivity & Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations and large deletions/duplications will not be detected.
Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
|Component Test Code*||Component Chart Name||LOINC|
|0051731||Biotinidase Deficiency (BTD) Sequencing|
|2001339||BTD FGS Specimen|
- BTD mutation testing